JP2016534039A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016534039A5 JP2016534039A5 JP2016521270A JP2016521270A JP2016534039A5 JP 2016534039 A5 JP2016534039 A5 JP 2016534039A5 JP 2016521270 A JP2016521270 A JP 2016521270A JP 2016521270 A JP2016521270 A JP 2016521270A JP 2016534039 A5 JP2016534039 A5 JP 2016534039A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- item
- cancer
- immunoconjugate
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940127121 immunoconjugate Drugs 0.000 claims description 60
- 206010028980 Neoplasm Diseases 0.000 claims description 27
- 102100035139 Folate receptor alpha Human genes 0.000 claims description 24
- 101001023230 Homo sapiens Folate receptor alpha Proteins 0.000 claims description 24
- 201000011510 cancer Diseases 0.000 claims description 23
- 206010033128 Ovarian cancer Diseases 0.000 claims description 22
- 238000010186 staining Methods 0.000 claims description 18
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 17
- 230000037396 body weight Effects 0.000 claims description 11
- 238000003364 immunohistochemistry Methods 0.000 claims description 11
- 231100000419 toxicity Toxicity 0.000 claims description 11
- 230000001988 toxicity Effects 0.000 claims description 11
- 150000003431 steroids Chemical class 0.000 claims description 10
- 229920001184 polypeptide Polymers 0.000 claims description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 9
- FUHCFUVCWLZEDQ-UHFFFAOYSA-N 1-(2,5-dioxopyrrolidin-1-yl)oxy-1-oxo-4-(pyridin-2-yldisulfanyl)butane-2-sulfonic acid Chemical compound O=C1CCC(=O)N1OC(=O)C(S(=O)(=O)O)CCSSC1=CC=CC=N1 FUHCFUVCWLZEDQ-UHFFFAOYSA-N 0.000 claims description 8
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 8
- 206010061137 Ocular toxicity Diseases 0.000 claims description 5
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 claims description 5
- 206010044245 Toxic optic neuropathy Diseases 0.000 claims description 5
- 239000000427 antigen Substances 0.000 claims description 5
- 102000036639 antigens Human genes 0.000 claims description 5
- 108091007433 antigens Proteins 0.000 claims description 5
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 5
- 229960003957 dexamethasone Drugs 0.000 claims description 5
- 239000012634 fragment Substances 0.000 claims description 5
- 231100000327 ocular toxicity Toxicity 0.000 claims description 5
- 229910052697 platinum Inorganic materials 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 11
- 239000013612 plasmid Substances 0.000 claims 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 3
- 230000002055 immunohistochemical effect Effects 0.000 claims 1
- 201000002628 peritoneum cancer Diseases 0.000 claims 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims 1
- 238000000034 method Methods 0.000 description 136
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 7
- 201000005202 lung cancer Diseases 0.000 description 7
- 208000020816 lung neoplasm Diseases 0.000 description 7
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 6
- ZOHXWSHGANNQGO-DSIKUUPMSA-N 1-amino-4-[[5-[[(2S)-1-[[(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl]oxy]-1-oxopropan-2-yl]-methylamino]-2-methyl-5-oxopentan-2-yl]disulfanyl]-1-oxobutane-2-sulfonic acid Chemical group CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCC(C)(C)SSCCC(C(N)=O)S(O)(=O)=O)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 ZOHXWSHGANNQGO-DSIKUUPMSA-N 0.000 description 4
- 208000003174 Brain Neoplasms Diseases 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 206010014733 Endometrial cancer Diseases 0.000 description 4
- 206010014759 Endometrial neoplasm Diseases 0.000 description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 4
- 206010038389 Renal cancer Diseases 0.000 description 4
- 208000002495 Uterine Neoplasms Diseases 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 201000010982 kidney cancer Diseases 0.000 description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 4
- 201000002528 pancreatic cancer Diseases 0.000 description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 description 4
- 206010046766 uterine cancer Diseases 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 3
- 208000009956 adenocarcinoma Diseases 0.000 description 3
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361888365P | 2013-10-08 | 2013-10-08 | |
| US201361888337P | 2013-10-08 | 2013-10-08 | |
| US61/888,337 | 2013-10-08 | ||
| US61/888,365 | 2013-10-08 | ||
| US201461948363P | 2014-03-05 | 2014-03-05 | |
| US61/948,363 | 2014-03-05 | ||
| US201462004815P | 2014-05-29 | 2014-05-29 | |
| US62/004,815 | 2014-05-29 | ||
| PCT/US2014/059716 WO2015054400A2 (en) | 2013-10-08 | 2014-10-08 | Anti-folr1 immunoconjugate dosing regimens |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018208158A Division JP6581279B2 (ja) | 2013-10-08 | 2018-11-05 | 抗ｆｏｌｒ１免疫抱合体投薬レジメン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016534039A JP2016534039A (ja) | 2016-11-04 |
| JP2016534039A5 true JP2016534039A5 (OSRAM) | 2017-11-16 |
| JP6463744B2 JP6463744B2 (ja) | 2019-02-06 |
Family
ID=52813740
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016521270A Active JP6463744B2 (ja) | 2013-10-08 | 2014-10-08 | 抗ｆｏｌｒ１免疫抱合体投薬レジメン |
| JP2018208158A Active JP6581279B2 (ja) | 2013-10-08 | 2018-11-05 | 抗ｆｏｌｒ１免疫抱合体投薬レジメン |
| JP2019156399A Withdrawn JP2019218386A (ja) | 2013-10-08 | 2019-08-29 | 抗ｆｏｌｒ１免疫抱合体投薬レジメン |
| JP2021125147A Active JP7386208B2 (ja) | 2013-10-08 | 2021-07-30 | 抗ｆｏｌｒ１免疫抱合体投薬レジメン |
| JP2023192883A Pending JP2024016239A (ja) | 2013-10-08 | 2023-11-13 | 抗ｆｏｌｒ１免疫抱合体投薬レジメン |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018208158A Active JP6581279B2 (ja) | 2013-10-08 | 2018-11-05 | 抗ｆｏｌｒ１免疫抱合体投薬レジメン |
| JP2019156399A Withdrawn JP2019218386A (ja) | 2013-10-08 | 2019-08-29 | 抗ｆｏｌｒ１免疫抱合体投薬レジメン |
| JP2021125147A Active JP7386208B2 (ja) | 2013-10-08 | 2021-07-30 | 抗ｆｏｌｒ１免疫抱合体投薬レジメン |
| JP2023192883A Pending JP2024016239A (ja) | 2013-10-08 | 2023-11-13 | 抗ｆｏｌｒ１免疫抱合体投薬レジメン |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US20150132323A1 (OSRAM) |
| EP (3) | EP4424323A3 (OSRAM) |
| JP (5) | JP6463744B2 (OSRAM) |
| KR (7) | KR20240027861A (OSRAM) |
| CN (1) | CN106164093A (OSRAM) |
| AU (4) | AU2014331964C1 (OSRAM) |
| BR (1) | BR112016007479A2 (OSRAM) |
| CA (1) | CA2926325C (OSRAM) |
| CY (1) | CY1122449T1 (OSRAM) |
| DK (2) | DK3653228T3 (OSRAM) |
| ES (2) | ES2759426T3 (OSRAM) |
| FI (1) | FI3653228T3 (OSRAM) |
| HR (2) | HRP20240917T1 (OSRAM) |
| HU (2) | HUE046696T2 (OSRAM) |
| IL (4) | IL298044B2 (OSRAM) |
| LT (2) | LT3055332T (OSRAM) |
| MX (2) | MX384973B (OSRAM) |
| MY (1) | MY174670A (OSRAM) |
| NZ (2) | NZ718766A (OSRAM) |
| PL (2) | PL3055332T3 (OSRAM) |
| PT (2) | PT3055332T (OSRAM) |
| RS (2) | RS59644B1 (OSRAM) |
| RU (1) | RU2696579C2 (OSRAM) |
| SG (3) | SG10202102555TA (OSRAM) |
| SI (2) | SI3653228T1 (OSRAM) |
| SM (1) | SMT201900694T1 (OSRAM) |
| UA (1) | UA119541C2 (OSRAM) |
| WO (1) | WO2015054400A2 (OSRAM) |
| ZA (1) | ZA201902009B (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230044026A (ko) | 2010-02-24 | 2023-03-31 | 이뮤노젠 아이엔씨 | 엽산염 수용체 1 항체와 면역접합체 및 이들의 용도 |
| UA125636C2 (uk) | 2011-04-01 | 2022-05-11 | Іммуноджен, Інк. | Способи ідентифікації раку, який може реагувати на анти-folr1 антитіло або анти-folr1 імунокон'югат |
| JP6293147B2 (ja) | 2012-08-31 | 2018-03-14 | イミュノジェン， インコーポレイテッド | 葉酸受容体１の検出のための診断分析およびキット |
| RU2015149285A (ru) * | 2013-05-14 | 2017-06-19 | Иммьюноджен Инк. | Схемы дозирования иммуноконъюгата anti-folr1 |
| LT3038650T (lt) | 2013-08-30 | 2021-09-10 | Immunogen, Inc. | Antikūnai ir foliatų receptoriaus 1 nustatymo testai |
| EP3349796A4 (en) * | 2015-09-17 | 2019-05-29 | ImmunoGen, Inc. | THERAPEUTIC COMBINATIONS WITH ANTI-FOLR1 IMMUNOCONJUGATES |
| CN118078987A (zh) * | 2017-05-16 | 2024-05-28 | 伊缪诺金公司 | 抗folr1免疫缀合物与抗pd-1抗体的组合 |
| US10596270B2 (en) | 2017-09-18 | 2020-03-24 | Sutro Biopharma, Inc. | Anti-folate receptor antibody conjugates, compositions comprising anti-folate receptor antibody conjugates, and methods of making and using anti-folate receptor antibody conjugates |
| KR102808710B1 (ko) | 2018-03-13 | 2025-05-15 | 페인스 테라퓨틱스 인코포레이티드 | 항-폴레이트 수용체 1 항체 및 이의 용도 |
| CA3105415A1 (en) * | 2018-07-09 | 2020-01-23 | Multitude Inc. | Antibodies specific to folate receptor alpha |
| TWI872065B (zh) | 2019-04-29 | 2025-02-11 | 美商免疫遺傳股份有限公司 | 雙互補位ＦＲ－α抗體及免疫結合物 |
| JP2024522544A (ja) * | 2021-06-04 | 2024-06-21 | イミュノジェン， インコーポレイテッド | 可溶性ＦＲ－α患者におけるがんの治療 |
| US20240408228A1 (en) * | 2021-12-01 | 2024-12-12 | Sutro Biopharma, Inc. | Anti-folate receptor conjugate cancer therapy |
| JP2024547111A (ja) * | 2021-12-24 | 2024-12-26 | バイオ－テラ ソリュ－ションズ，エルティーディー． | 抗ＦＲα抗体及びその抗体薬物コンジュゲート並びに使用 |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3896111A (en) | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
| US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
| US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
| JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
| JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
| JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
| EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
| JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
| WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
| US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
| US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
| US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
| US4563304A (en) | 1981-02-27 | 1986-01-07 | Pharmacia Fine Chemicals Ab | Pyridine compounds modifying proteins, polypeptides or polysaccharides |
| JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6100064A (en) | 1984-04-06 | 2000-08-08 | Chiron Corporation | Secreted viral proteins useful for vaccines and diagnostics |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
| ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
| ES2149768T3 (es) | 1992-03-25 | 2000-11-16 | Immunogen Inc | Conjugados de agentes enlazantes de celulas derivados de cc-1065. |
| ES2176484T3 (es) | 1995-08-18 | 2002-12-01 | Morphosys Ag | Bancos de proteinas/(poli)peptidos. |
| US6706484B1 (en) | 1995-08-18 | 2004-03-16 | Morphosys Ag | Protein/(poly)peptide libraries |
| US6544787B1 (en) * | 1996-11-15 | 2003-04-08 | Hadash Medical Research Services And Development Ltd. | Non-myeloablative/lymphoablative conditioning regimen to induce patient anti-donor unresponsiveness in stem cell transplantation |
| ES2353268T3 (es) | 1999-07-02 | 2011-02-28 | Morphosys Ag | Generacion de elementos de union especifica que se unen a (poli)peptidos codificados por fragmentos de adn genomico o est. |
| US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
| US20020151508A1 (en) * | 2001-02-09 | 2002-10-17 | Schering Corporation | Methods for treating proliferative diseases |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| US6716821B2 (en) | 2001-12-21 | 2004-04-06 | Immunogen Inc. | Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same |
| GB0202319D0 (en) | 2002-02-01 | 2002-03-20 | Calex Electronics Ltd | Apparatus |
| WO2004082463A2 (en) * | 2003-03-17 | 2004-09-30 | Medical College Of Ohio | Folate receptor gene modulation for cancer diagnosis and therapy |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| US20080312425A1 (en) | 2004-08-30 | 2008-12-18 | Lonza Biologics Plc. | Ion Exchange Chromatography and Purification of Antibodies |
| AU2006230219A1 (en) * | 2005-03-30 | 2006-10-05 | Endocyte, Inc. | Method for cancer prognosis using cellular folate vitamin receptor quantification |
| EP1937307A4 (en) * | 2005-09-14 | 2009-05-13 | Hutchinson Fred Cancer Res | SPECIFIC REMOVAL OF ACTIVATED IMMUNOCELLS |
| EP1900752A1 (en) * | 2006-09-15 | 2008-03-19 | DOMPE' pha.r.ma s.p.a. | Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma |
| US7691980B2 (en) | 2007-01-09 | 2010-04-06 | Bio-Rad Laboratories, Inc. | Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers |
| US8093364B2 (en) | 2008-01-18 | 2012-01-10 | Bio-Rad Laboratories, Inc. | Enhanced purification of antibodies and antibody fragments by apatite chromatography |
| WO2009094456A2 (en) * | 2008-01-22 | 2009-07-30 | Johns Hopkins University | Use of high-dose, post-transplantation oxazaphosphorine drugs for reduction of transplant rejection |
| CN104524590B (zh) | 2008-04-30 | 2019-06-21 | 伊缪诺金公司 | 交联剂和它们的用途 |
| MX2010011808A (es) | 2008-04-30 | 2011-03-04 | Immunogen Inc | Conjugados potentes y enlazadores hidrofilicos. |
| LT2378876T (lt) * | 2008-12-19 | 2019-04-25 | Medicis Pharmaceutical Corporation | Mažesnio stiprumo dozės imikvimodo kompozicijos ir trumpi dozavimo režimai, skirti aktininės keratozės gydymui |
| IN2012DN02826A (OSRAM) * | 2009-10-21 | 2015-07-24 | Immunogen Inc | |
| KR20230044026A (ko) * | 2010-02-24 | 2023-03-31 | 이뮤노젠 아이엔씨 | 엽산염 수용체 1 항체와 면역접합체 및 이들의 용도 |
| US8530122B2 (en) | 2010-07-30 | 2013-09-10 | Konica Minolta Business Technologies, Inc. | Foil transferring face forming toner and image forming method |
| WO2012061759A2 (en) * | 2010-11-05 | 2012-05-10 | Morphotek Inc. | Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers |
| UA125636C2 (uk) * | 2011-04-01 | 2022-05-11 | Іммуноджен, Інк. | Способи ідентифікації раку, який може реагувати на анти-folr1 антитіло або анти-folr1 імунокон'югат |
| WO2012138749A1 (en) | 2011-04-04 | 2012-10-11 | Immunogen, Inc. | Methods for decreasing ocular toxicity of antibody drug conjugates |
| JP6293147B2 (ja) * | 2012-08-31 | 2018-03-14 | イミュノジェン， インコーポレイテッド | 葉酸受容体１の検出のための診断分析およびキット |
| EA032775B1 (ru) * | 2013-04-08 | 2019-07-31 | Берг Ллк | Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10 |
| RU2015149285A (ru) * | 2013-05-14 | 2017-06-19 | Иммьюноджен Инк. | Схемы дозирования иммуноконъюгата anti-folr1 |
| LT3038650T (lt) * | 2013-08-30 | 2021-09-10 | Immunogen, Inc. | Antikūnai ir foliatų receptoriaus 1 nustatymo testai |
| EP3349796A4 (en) * | 2015-09-17 | 2019-05-29 | ImmunoGen, Inc. | THERAPEUTIC COMBINATIONS WITH ANTI-FOLR1 IMMUNOCONJUGATES |
-
2014
- 2014-10-08 WO PCT/US2014/059716 patent/WO2015054400A2/en not_active Ceased
- 2014-10-08 RU RU2016114708A patent/RU2696579C2/ru active
- 2014-10-08 KR KR1020247005572A patent/KR20240027861A/ko active Pending
- 2014-10-08 SG SG10202102555TA patent/SG10202102555TA/en unknown
- 2014-10-08 SM SM20190694T patent/SMT201900694T1/it unknown
- 2014-10-08 MX MX2016004411A patent/MX384973B/es unknown
- 2014-10-08 SI SI201432085T patent/SI3653228T1/sl unknown
- 2014-10-08 NZ NZ718766A patent/NZ718766A/en unknown
- 2014-10-08 DK DK19199163.7T patent/DK3653228T3/da active
- 2014-10-08 RS RS20191523A patent/RS59644B1/sr unknown
- 2014-10-08 PL PL14852834T patent/PL3055332T3/pl unknown
- 2014-10-08 EP EP24170072.3A patent/EP4424323A3/en not_active Withdrawn
- 2014-10-08 DK DK14852834T patent/DK3055332T3/da active
- 2014-10-08 SG SG11201602361UA patent/SG11201602361UA/en unknown
- 2014-10-08 MY MYPI2016000551A patent/MY174670A/en unknown
- 2014-10-08 CN CN201480055444.3A patent/CN106164093A/zh active Pending
- 2014-10-08 KR KR1020167012025A patent/KR102115217B1/ko active Active
- 2014-10-08 AU AU2014331964A patent/AU2014331964C1/en active Active
- 2014-10-08 ES ES14852834T patent/ES2759426T3/es active Active
- 2014-10-08 BR BR112016007479A patent/BR112016007479A2/pt not_active Application Discontinuation
- 2014-10-08 NZ NZ757964A patent/NZ757964A/en unknown
- 2014-10-08 LT LTEP14852834.2T patent/LT3055332T/lt unknown
- 2014-10-08 KR KR1020207014364A patent/KR20200058592A/ko not_active Ceased
- 2014-10-08 KR KR1020237034405A patent/KR102639861B1/ko active Active
- 2014-10-08 SG SG10201907042PA patent/SG10201907042PA/en unknown
- 2014-10-08 KR KR1020217010200A patent/KR102303874B1/ko active Active
- 2014-10-08 LT LTEP19199163.7T patent/LT3653228T/lt unknown
- 2014-10-08 PT PT148528342T patent/PT3055332T/pt unknown
- 2014-10-08 HU HUE14852834A patent/HUE046696T2/hu unknown
- 2014-10-08 EP EP14852834.2A patent/EP3055332B1/en active Active
- 2014-10-08 US US14/509,809 patent/US20150132323A1/en active Pending
- 2014-10-08 UA UAA201604168A patent/UA119541C2/uk unknown
- 2014-10-08 EP EP19199163.7A patent/EP3653228B1/en active Active
- 2014-10-08 SI SI201431419T patent/SI3055332T1/sl unknown
- 2014-10-08 HR HRP20240917TT patent/HRP20240917T1/hr unknown
- 2014-10-08 ES ES19199163T patent/ES2983055T3/es active Active
- 2014-10-08 FI FIEP19199163.7T patent/FI3653228T3/fi active
- 2014-10-08 HR HRP20192140TT patent/HRP20192140T1/hr unknown
- 2014-10-08 IL IL298044A patent/IL298044B2/en unknown
- 2014-10-08 PL PL19199163.7T patent/PL3653228T3/pl unknown
- 2014-10-08 HU HUE19199163A patent/HUE067367T2/hu unknown
- 2014-10-08 IL IL313730A patent/IL313730A/en unknown
- 2014-10-08 KR KR1020217029508A patent/KR20210118220A/ko not_active Ceased
- 2014-10-08 JP JP2016521270A patent/JP6463744B2/ja active Active
- 2014-10-08 RS RS20240830A patent/RS65798B1/sr unknown
- 2014-10-08 KR KR1020227033036A patent/KR20220136468A/ko not_active Ceased
- 2014-10-08 CA CA2926325A patent/CA2926325C/en active Active
- 2014-10-08 PT PT191991637T patent/PT3653228T/pt unknown
-
2016
- 2016-03-27 IL IL244772A patent/IL244772B/en active IP Right Grant
- 2016-04-06 MX MX2021009222A patent/MX2021009222A/es unknown
-
2018
- 2018-11-05 JP JP2018208158A patent/JP6581279B2/ja active Active
- 2018-12-11 AU AU2018278880A patent/AU2018278880A1/en not_active Abandoned
-
2019
- 2019-03-24 IL IL265586A patent/IL265586A/en unknown
- 2019-03-28 ZA ZA2019/02009A patent/ZA201902009B/en unknown
- 2019-08-29 JP JP2019156399A patent/JP2019218386A/ja not_active Withdrawn
- 2019-12-02 CY CY20191101260T patent/CY1122449T1/el unknown
-
2020
- 2020-11-03 AU AU2020264270A patent/AU2020264270B2/en active Active
-
2021
- 2021-01-15 US US17/150,379 patent/US20210155688A1/en not_active Abandoned
- 2021-07-30 JP JP2021125147A patent/JP7386208B2/ja active Active
-
2023
- 2023-11-13 JP JP2023192883A patent/JP2024016239A/ja active Pending
-
2024
- 2024-03-12 AU AU2024201615A patent/AU2024201615A1/en active Pending
- 2024-04-12 US US18/634,736 patent/US20240368270A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016534039A5 (OSRAM) | ||
| JP2016520082A5 (OSRAM) | ||
| CA3071383C (en) | Anti-cd137 antibodies | |
| CN106459200B (zh) | 抗-egfr抗体及抗体药物偶联物 | |
| JP2021059564A (ja) | 癌治療のための併用療法 | |
| JP2019031568A5 (OSRAM) | ||
| JP2022058802A5 (OSRAM) | ||
| JP2011507932A5 (OSRAM) | ||
| JP2018534933A5 (OSRAM) | ||
| JP2020508317A5 (OSRAM) | ||
| FI3394103T3 (fi) | Anti-PD-1-vasta-aineiden ja bispesifisten anti-CD20-/anti-CD3-vasta-aineiden yhdistelmä syövän hoitoon | |
| JP2018527383A5 (OSRAM) | ||
| EP3008093A1 (en) | Anti-her2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer | |
| RU2018111205A (ru) | Терапевтические комбинации, содержащие анти-folr1 иммуноконъюгаты | |
| CA3196940A1 (en) | Anti-her3 antibody and anti-her3 antibody-drug conjugate and medical use thereof | |
| RU2016114708A (ru) | Схемы применения иммуноконъюгата анти-folr1 | |
| TWI895608B (zh) | 抗c-Met抗體藥物結合物 | |
| IL278574B1 (en) | Compounds acting on glycans and methods of using them | |
| JP2013520442A5 (OSRAM) | ||
| RU2019141270A (ru) | Комбинации анти-folr1 иммуноконъюгатов и анти-pd-1 антител | |
| CA3093731A1 (en) | Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor | |
| IL312038A (en) | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer | |
| CA3232806A1 (en) | B7-h4 antibody-drug conjugates for the treatment of cancer | |
| KR20250044188A (ko) | 캄프토테신계 유도체 및 리간드-약물 접합체 | |
| JP2024515618A (ja) | 抗腫瘍処置における抗体の使用 |